Short-term efficacy of faricimab switch on retinal exudative signs in patients requiring frequent anti-VEGF injections : A real-life study
- 1 September 2025
- journal article
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 36 (2) , 321-329
Abstract
Objective: To evaluate the efficacy of switching from anti-vascular endothelial growth factor (VEGF) to faricimab in reducing exudative signs in age-related macular degeneration (AMD) patients receiving regular injections (every 8 weeks or less) without restarting a standard induction regimen. Methods: This retrospective, observational, multicenter study included patients with exudative AMD previously treated with aflibercept 2 mg or ranibizumab every ≤8 weeks and switched to faricimab while maintaining their previous injection interval. The first follow-up visit occured after switching to faricimab, with a single injection, and corresponded to the pre-existing injection interval. Primary outcomes included changes in subretinal (SRF) and intraretinal fluid (IRF). Results: Among 39 patients (47 eyes), the proportion of eyes with SRF decreased from 43.1% to 23.5% ( p < 0.01) and IRF from 43.8% to 19.6% ( p < 0.01). SRF height significantly reduced from 75.3 μm to 60 μm ( p = 0.04). Pigment epithelial detachment (PED) height decreased from 223 μm to 164μm ( p < 0.01), and central retinal thickness (CRT) declined from 273.7 μm to 268 μm ( p < 0.01). Injection intervals extended by an average of 7 days (40 to 47 days, p < 0.01). No significant changes in BCVA ( p = 0.14) were observed. No adverse events were reported. Conclusions: Switching to faricimab without restarting an induction phase effectively reduces SRF and IRF while modestly extending injection intervals in patients requiring frequent anti-VEGF injections. These findings suggest a potential benefit in treatment burden reduction. Further studies are needed to assess long-term visual outcomes and safety.Keywords
This publication has 28 references indexed in Scilit:
- Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degenerationInternational Ophthalmology, 2024
- Short-term outcomes of treatment switch to faricimab in patients with aflibercept-resistant neovascular age-related macular degenerationGraefe's Archive for Clinical and Experimental Ophthalmology, 2024
- TENAYA and LUCERNEOphthalmology, 2024
- Outcomes of Treatment-Resistant Neovascular Age-Related Macular Degeneration Switched from Aflibercept to FaricimabOphthalmology Retina, 2023
- Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degenerationGraefe's Archive for Clinical and Experimental Ophthalmology, 2023
- Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trialsThe Lancet, 2022
- Loss to Follow-up Among Patients With Neovascular Age-Related Macular Degeneration Who Received Intravitreal Anti–Vascular Endothelial Growth Factor InjectionsJAMA Ophthalmology, 2018
- Psychological impact of anti-VEGF treatments for wet macular degeneration—a reviewGraefe's Archive for Clinical and Experimental Ophthalmology, 2016
- Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysisThe Lancet Global Health, 2014
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular DegenerationOphthalmology, 2012